the most active metabolite of vitamin D, controls paraBackground. Calcitriol, 1,25-(OH) 2 D 3 (1,25D), the most ac-
Secondary hyperparathyroidism is a common complica- tients on chronic hemodialysis, and the use of calcium
Results. In uremic rats, 19-nor did not increase plasma Ca or P while 1␣D 2 caused a dose-dependent increase in both. In acetate or calcium carbonate as a phosphate binder only addition, while the Ca ϫ P product remained unchanged in increases the risk of hypercalcemia from 1,25-(OH) 2 D 3 19-nor-treated rats, it increased progressively with 1␣D 2 admintherapy [10] . The recent development of vitamin D anaistration. In metabolic studies in normal rats treated with vehilogs that retain many of the therapeutic properties of cle, 10 ng of 1,25D, 100 ng of 19-nor or 100 ng 1␣D 2 , intestinal 1,25-(OH) 2 D 3 but have less calcemic and phosphatemic calcium absorption and urinary calcium excretion were significantly higher in 1␣D 2 -treated rats compared to those receiving activity has been a major advancement in vitamin D 19-nor. Similar results were seen for intestinal phosphorus abtherapies [11] [12] [13] . Some of these vitamin D analogs dissorption and urinary phosphorus excretion. Finally, the skeletal play high differentiating and antiproliferative activities response to these two analogs was tested in PTX rats fed a in leukemic cells, breast cancer cells and psoriatic fibrocalcium-deficient diet and treated daily with 100 ng of 19-nor blasts and keratinocytes [14] [15] [16] [17] [18] [19] [20] [21] as well as modulate the or 1␣D 2 . The increase in plasma calcium in 1␣D 2 -treated rats was markedly higher than in those receiving 19-nor. Similar immune system [22] . In addition, these analogs seem to results were seen in plasma phosphorus when these studies have less of an effect on mineral metabolism at their were repeated using a phosphorus-deficient diet.
effective doses.
Conclusions. These studies demonstrate that when given in
Previous studies from our laboratory demonstrated that large doses to rats 19-nor is less calcemic and phosphatemic 19-nor-1,25-(OH) 2 D 2 (19-nor), an analog of 1,25-(OH) 2 D 3 , than 1␣D 2 . The lower Ca ϫ P product in 19-nor treated rats may be an important consideration in patient therapy. Further suppresses PTH levels in uremic rats at doses that did studies in patients are necessary to define the clinical applicabilnot increase plasma ionized calcium levels [23, 24] . Moreity of these differences.
over, in contrast to 1,25-(OH) 2 D 3 , 19-nor had no effect on plasma phosphorus levels. 19-nor (Zemplar) is currently being used for the treatment of secondary hyper-shown to be effective in reducing plasma PTH levels in hemodialysis patients who display moderate to severe  2002 by the International Society of Nephrology hyperparathyroidism [25, 26] . In contrast to 19-nor, this
Heat muffle oven (Blue M Corporation, Blue Island, IL, compound is a pro-hormone and must be activated by USA). The ash was dissolved in concentrated hydrochlothe liver by the addition of a hydroxyl group at carbon ric acid and analyzed for calcium and phosphorus. Prior 25 before this vitamin D analog is active. The purpose to the study, the diet also was analyzed for calcium and of the present study was to compare, in normal and phosphorus using the same method. The net amount of uremic rats, the calcemic and phosphatemic effects of intestinal calcium or phosphorus absorbed was expressed these two vitamin D analogs, 19-nor and 1␣D 2 .
as the percent of ingested calcium or phosphorus not appearing in the feces. Normal parathyroidectomized (PTX) rats were used hormone in uremic rats in this study to eliminate the effects of 19-nor and 1␣D 2 Renal insufficiency was induced in a group of 66 feon PTH synthesis and secretion, and to provide a wider male Sprague-Dawley rats by 5/6 nephrectomy. This prorange of calcium levels in which to evaluate these two cedure involves the ligation of most of the branches of compounds. Parathyroid glands were removed microsurthe left renal artery followed by right nephrectomy. The gically from a group of 15 female Sprague-Dawley rats animals were divided into seven groups. Group 1 reweighing 225 to 250 grams. Rats were fasted overnight and ceived vehicle and served as the uremic control group.
METHODS
blood was drawn to confirm parathyroidectomy. Only Groups 2, 3, and 4 received 50, 100, or 250 ng of 19-nor, animals with a plasma total calcium less than 7 mg/dL respectively, intraperitoneally three times a week for two were used in this study. A diet deficient in calcium was weeks, and groups 5, 6, and 7 received, 50, 100, or 250 used to eliminate the contribution of intestinal absorpng of 1␣D 2 intraperitoneally three times a week for two tion to plasma calcium levels. Parathyroidectomized rats weeks. Six normal rats served as the normal control. At were fed a diet containing 0.02% calcium and 0.35% the end of the study the animals were euthanized and phosphorus and received daily intraperitoneal injections blood was obtained for total and ionized calcium, phosof vehicle (propylene glycol), or 100 ng of 19-nor or 1␣D 2 phorus, creatinine and parathyroid hormone. The rats for a period of 35 days. Blood was obtained from the were fed a rodent chow containing 0.9% calcium and tail every two to three days for the first 11 days and then 0.55% phosphorus.
at days 18 and 35 for plasma calcium determinations.
Metabolic studies in normal rats
Phosphatemic response to 19-nor-1,25-(OH) 2 D 2 and Blood was drawn from the tail of 28 normal female 1␣(OH)D 2 in parathyroidectomized rats Sprague-Dawley rats weighing 225 to 250 grams for the determination of plasma calcium and phosphorus. The Studies were performed as described in the last section animals were then divided into four groups and placed of this article, except that in this study a group of 23 in group housing, and treatment was begun. The rats PTX rats were fed a phosphorus deficient diet (0.02% received daily injections of (1) vehicle (100 L propylene phosphorus, 0.5% calcium). In addition, the rats received glycol), (2) 10 ng of 1,25-(OH) 2 D 3 , (3) 100 ng of 19-nor, daily intraperitoneal injections of vehicle (propylene glyor (4) 100 ng of 1␣D 2 for 14 days, and were given free col) or 200 ng of 19-nor or 1␣D 2 for a period of 10 days. access to deionized water and normal rodent chow conBlood samples were obtained from the tail as previously taining 0.90% calcium and 0.55% phosphorus. We chose described on days 0, 2, 4, 6, 8, and 11 for plasma phosphothe same dose of 19-nor and 1␣D 2 for comparison. The rus determinations. dose of 1,25-(OH) 2 D 3 was derived from previous studies. On the last four days of treatment the rats were placed Analytical determinations in metabolic cages. Twenty-four hour urine and feces Total calcium was measured using an atomic absorpwere collected and daily dietary intake monitored. Retion spectrophotometer (model 1100B; Perkin-Elmer, sults are taken from the mean of the last three days of Norwalk, CT, USA). Ionized calcium was measured ustreatment. At the end of the study, rats were euthanized ing an ionized specific-calcium electrode (model ICA-1; and blood was taken for the measurement of ionized Radioneter, Copenhagen, Denmark). Plasma creatinine, calcium, total calcium and phosphorus. The urine was blood urea nitrogen (BUN) and phosphorus were deteracidified and each 24-hour urine sample was analyzed mined by autoanalyzer (Mira Plus; COBAS, Branchfor calcium and phosphorus. Urinary excretion is exburg, NJ, USA). Intact PTH was measured using a immupressed as total calcium or phosphorus excreted in mg noradiometric assay specific for rat PTH (Immutopics, per 24 hours. Feces for each 24-hour period were dried in a drying oven at 100ЊC and ashed overnight in a Lab San Clemente, CA, USA). 
Statistical analysis
All results are expressed as mean Ϯ SEM. One way analysis of variance (ANOVA) was used for comparison (OH) 2 D 2 affected the Ca ϫ P product ( , N ϭ 10) while 1␣(OH)D 2 caused a progressive increase in the Ca ϫ P product ( , N ϭ 9). *P Ͻ 0.01 vs. control rats; **P Ͻ 0.001 vs. control rats.
RESULTS

Effects of 19-nor-1, 25-(OH) 2 D 2 and 1␣(OH)D 2 in uremic rats
normal rats (50.3 Ϯ 13.2 pg/mL). Although complete Table 1 shows the effects of two weeks of treatment suppression of PTH (Ͻ2 pg/mL) was seen in rats treated with 19-nor or 1␣D 2 on plasma creatinine, ionized calwith 100 and 250 ng of 1␣D 2 , this was accompanied by cium, phosphorus and PTH in the uremic rats. The ada marked increase in plasma-ionized calcium (1␣D 2 100 ministration of 19-nor (50, 100,or 250 ng) did not increase ng, 5.46 Ϯ 0.09 mg/dL and 1␣D 2 250 ng, 5.34 Ϯ 0.16 ionized calcium or phosphorus. On the other hand, the mg/dL vs. uremic control, 4.62 Ϯ 0.13 mg/dL, P Ͻ 0.001). administration of the same dose of 1␣D 2 produced a By comparison, the same dose of 19-nor (100 ng) supdose dependent increase in both blood chemistries.
pressed the increase in PTH seen in the uremic control The administration of 50 ng of 19-nor suppressed the group by almost 70% (58.2 Ϯ 9.4 pg/mL) but did not increase in PTH seen in uremic rats treated with vehicle increase plasma ionized calcium (4.57 Ϯ 0.08 mg/dL) or alone (19-nor, 76.3 Ϯ 16.0 pg/mL versus uremic control, phosphorus (5.24 Ϯ 0.24 mg/dL). 185 Ϯ 115 pg/mL). The same dose of 1␣D 2 , however, Examination of the Ca ϫ P product (Fig. 1 ) revealed did not significantly suppress the increase in PTH that none of the doses of 19-nor increased this parameter (138.9 Ϯ 41.1 pg/mL). The PTH level in rats treated with above that seen in the uremic control group (control, the 50 ng dose of 19-nor was significantly lower than 67.2 Ϯ 7.9; 19-nor 50 ng, 59.6 Ϯ 5.9; 19-nor 100 mg, 48.7 Ϯ that of rats treated with the 50 ng dose of 1␣D 2 (P Ͻ 2.3; 19-nor 250 mg, 64.3 Ϯ 7.2 mg 2 /dL 2 ). In contrast, both 0.01). In addition, PTH levels in rats treated with 100 ng the 100 ng and 250 ng doses of 1␣D 2 caused a marked or 250 ng of 19-nor (100 ng, 58.2 Ϯ 9.4 pg/mL; 250 ng, 54.6 Ϯ 14.0 pg/mL) were not different from those of increased in the Ca ϫ P product (100 ng, 94.6 Ϯ 4.8 mg D 3 (, N ϭ 7) in normal rats. The administration of 10 ng of 1,25-(OH) 2 D 3 (, N ϭ or 100 ng of 1␣(OH)D 2 ( , N ϭ 7) for 14 days produced a significant 7) or 100 ng of 1␣(OH)D 2 ( , N ϭ 7) for 14 days produced a significant increase in intestinal calcium absorption compared to control rats reincrease in intestinal phosphorus absorption compared to control rats ceiving vehicle alone (ᮀ, N ϭ 7; P Ͻ 0.01) or to rats receiving 100 ng receiving vehicle alone (ᮀ, N ϭ 7; P Ͻ 0.01) or to rats receiving 100 of 19-nor-1,25-(OH) 2 D 2 ( , N ϭ 7; P Ͻ 0.05). On the other hand, ng of 19-nor-1,25-(OH) 2 D 2 ( , N ϭ 7; P Ͻ 0.01). In addition, the the administration of 19-nor-1,25-(OH) 2 D 2 did not increase intestinal administration of 19-nor-1,25-(OH) 2 D 2 did not increase intestinal phoscalcium absorption compared to control rats. *P Ͻ 0.01 vs. control rats;
phorus absorption compared to control rats alone. *P Ͻ 0.01 vs. control †P Ͻ 0.01 vs. 19-nor-treated rats.
rats; †P Ͻ 0.01 vs. 19-nor-treated rats. 
Metabolic studies in normal rats
The effects of 1,25-(OH) 2 D 3 (10 ng), and 100 ng of 19-nor or 1␣D 2 on the intestinal absorption of calcium and phosphorus and on the urinary excretion of calcium and phosphorus were studied in a group of normal rats. The intestinal absorption of calcium increased from 23.9 Ϯ 2.30% in control rats to 32.8 Ϯ 1.34% in rats receiving 1,25-(OH) 2 D 3 , to 27.1 Ϯ 1.11% in rats treated with 19-nor and to 32.7 Ϯ 2.15% after the administration (Fig. 2) . The intestinal calcium absorption seen rats. The administration of 10 ng of 1,25-(OH) 2 D 3 (, N ϭ 7) or 100 after the administration of both 1,25-(OH) 2 D 3 and 1␣D 2 ng of 1␣(OH)D 2 ( , N ϭ 7), for 14 days produced a marked increase was significantly higher than that of rats receiving vehicle in urinary calcium excretion compared to control rats receiving vehicle alone (ᮀ, N ϭ 7) (P Ͻ 0.01). While the 100 ng of 19-nor-1,25-(OH) 2 D 2 alone (P Ͻ 0.01). The intestinal calcium absorption after ( , N ϭ 7) produced a modest increase in urinary calcium excretion treatment with 19-nor was not statistically different than compared to the control group (P Ͻ 0.05) this increase was significantly that of control rats.
less than that seen in rats receiving either 1,25-(OH) 2 D 3 (P Ͻ 0.01) or the same dose of 1␣(OH)D 2 (P Ͻ 0.001). *P Ͻ 0.05 vs. control rats; Similar effects were observed with intestinal phospho-**P Ͻ 0.01 vs. control rats. ***P Ͻ 0.001 vs. control rats; †P Ͻ 0.01 rus absorption (Fig. 3) . Intestinal absorption of phosphovs. 19-nor-treated rats; and † †P Ͻ 0.001 vs. 19-nor-treated rats.
rus increased significantly in 1,25D-treated rats (44.7 Ϯ 1.14%, P Ͻ 0.01) and in rats receiving 1␣D 2 (45.0 Ϯ 1.6%, P Ͻ 0.01) compared to vehicle-treated rats (36.1 Ϯ 1.8%). The administration 19-nor had no effect on intesincreased urinary calcium excretion to 21.9 Ϯ 2.5 mg/24 h (P Ͻ 0.01). The urinary calcium in 1␣D 2 treated rats was tinal phosphorus absorption (37.7 Ϯ 1.58%). The increase in phosphorus absorption seen after treatment similar to that seen in 1,25-(OH) 2 D 3 treated rats. The urinary calcium excretion in 19-nor-treated rats, howwith 1,25-(OH) 2 D 3 or 1␣D 2 were significantly greater (P Ͻ 0.01) than that of 19-nor-treated rats.
ever, was significantly less than that seen with either 1,25-(OH) 2 D 3 (P Ͻ 0.01) or 1␣D 2 treatment (P Ͻ 0.01). As shown in Figure 4 , 24-hour urinary calcium excretion increased from 4.46 Ϯ 0.39 mg/24 h in control rats Figure 5 shows that 24-hour urinary phosphorus increased from 5.37 Ϯ 1.14 mg/24 h in the control group to 17.9 Ϯ 1.36 mg/24 h (P Ͻ 0.01) after treatment with 1,25-(OH) 2 D 3 , while 19-nor induced a more modest into 20.7 Ϯ 2.4 mg/24 h (P Ͻ 0.01) with 1,25-(OH) 2 D 3 treatment, to 24.7 Ϯ 2.7 mg/24 h (P Ͻ 0.01) in rats crease on urinary calcium excretion (10.5 Ϯ 1.25 mg/24 h, P Ͻ 0.05). In contrast to 19-nor, administration of 1␣D 2 receiving 1␣D 2 , but only to 10.9 Ϯ 1.21 mg/24 h (NS) in the 19-nor treated rats. As with urinary calcium, the increase in urinary phosphorus was not different between 1,25D and 1␣D 2 treated rats, but both of these groups had greater urinary P excretion compared to 19-nor (P Ͻ 0.01 and P Ͻ 0.001, respectively). Plasma total calcium was higher in the 1␣D 2 treated group compared to 19-nor-treated rats (10.9 Ϯ 0.19 vs 10.1 Ϯ 0.07 mg/dL). Plasma ionized Ca and phosphorus were similar in both (Fig. 6) . The increase in plasma calcium was significantly greater in 1␣D 2 treated rats than in those receiving 19-nor (P Ͻ DISCUSSION 0.001). Plasma calcium in vehicle-treated rats remained Chronic renal failure (CRF) is characterized by changes unchanged during the course of the study.
in mineral homeostasis, with secondary hyperparathyThe phosphatemic response to 19-nor and 1␣D 2 is roidism (SH) appearing even in the early stages of renal shown in Figure 7 . As expected, serum phosphorus iniinsufficiency leading to the development of renal osteotially increased after PTX from 7.14 Ϯ 0.39 to 10.7 Ϯ dystrophy [27] [28] [29] . Thus, controlling SH has been a pri-0.29 mg/dL. Thereafter the rats were fed a phosphate mary goal in the treatment patients with CRF. deficient diet and started on 200 ng daily of 19-nor or
The 1,25-(OH) 2 D 3 analog, 19-nor-1,25-(OH) 2 D 2 is cur-1␣D 2 . By the eleventh day of treatment serum phosphorently being used in the treatment of SH because it retains the ability of the parent compound to effectively rus increased from 4.93 Ϯ 0.20 mg/dL in control rats to suppress PTH, but produces significantly less hypercalceresorption of Ca and P by these two analogs. These studies also showed 1␣D 2 to be more potent than 19-nor in mobimia and hyperphosphatemia, providing a larger therapeutic window in which to treat patients. In a 12-week lizing Ca and P from bone at equivalent doses. While little is known about the mechanism of action multi-center clinical trial, Martin et al reported a 60% decrease in serum PTH in hemodialysis patients receivof 1␣D 2 , it is not surprising that it would have more potent calcemic and phosphatemic properties than 19-ing 19-nor compared to those receiving placebo [30] [26] . Since to our knowledge no studies have compared 70% less. Since osteoblasts and not osteoclasts express the vitamin D receptor (VDR), it was thought that there the efficacy of 19-nor and 1␣D 2 in treating SH, we compared the effect of these two compounds on plasma calmust be some factor(s) responsible for communication between these two cell types triggering osteoclastic bone cium, phosphorus and PTH in uremic rats and on intestinal Ca and P absorption and bone resorption in normal resorption. Recent studies have identified this protein as osteoprotegerin ligand (OPGL or RANKL) [36] [37] [38] . and PTX rats.
We first compared the ability of these two analogs to Holiday et al found that 19-nor, although seemingly as potent as 1,25-(OH) 2 D 3 in osteoclast recruitment, was suppress PTH in uremic rats. 19-nor suppressed PTH and without changes in serum ionized Ca or P, while less active in osteoclast activation [35] . The comparative effect of 19-nor on RANKL production is not known, 1␣D 2 suppressed PTH only at doses where a marked increase in serum Ca and P occurred. However, it is possibut recently Lacey et al found that a higher concentration of OPGL is required for osteoclast activation than for ble that on intermediate doses of 1␣D 2 , that is, 75 ng, could suppress serum PTH with little effect on serum osteoclast recruitment [36] . One possible explanation for the decreased osteoclast activity of 19-nor is that 19-nor calcium. Earlier in vitro studies from our laboratory showed that 19-nor can suppress PTH secretion in culmay induce RANKL to levels high enough for the recruitment of osteoclasts but not for their activation. This tured bovine parathyroid cells with the same potency as 1,25-(OH) 2 D 3 [23] . Although 19-nor is hypercalcemic at hypothesis requires further experimental confirmation. Our current study compares equal doses of 19-nor very high doses, it was also shown to suppress PTH levels in uremic rats at doses that did not affect serum Ca or (OH) 2 D 2 and 1␣(OH)D 2 . It is likely that even though 19-nor(OH) 2 D 2 is less calcemic than 1␣(OH)D 2 , serum P levels [23, 24] .
To further evaluate the higher calcemic response by levels of active hormone are higher in the 19-nor (OH) 2 D 2 -treated group than in rats receiving 1␣D 2 , since 1␣D 2 , we assessed the effects of the two compounds on intestinal calcium absorption and bone mineral mobiliza-1␣(OH)D 2 must first be converted to 1,25-(OH) 2 D 2 . The rate of conversion of 1␣D 2 to 1,25-(OH) 2 D 2 is not known, tion. Previous studies from our laboratory comparing 1,25-(OH) 2 D 3 and 19-nor showed 19-nor to be about 10 but is probably similar to the rate of conversion of 1␣(OH)D 3 to 1,25-(OH) 2 D 3 since the liver enzyme retimes less effective than 1,25(OH) 2 D 3 both in increasing intestinal Ca and P absorption [31] and in mobilizing Ca sponsible for this conversion, cytochrome p450, appears not differentiate between 1␣(OH)D 2 and 1␣(OH)D 3 [39] . and P from bone [32] . Our current study repeated these earlier studies comparing 19-nor and 1␣D 2 . In metabolic
In standard bioassays 1␣(OH)D 2 has been shown to be as effective as 1␣(OH)D 3 but is 5-to 15-fold less studies 19-nor was significantly less potent in increasing both intestinal Ca and P absorption than 1␣D 2 . In additoxic than 1␣(OH)D 3 in vivo [40, 41] . Studies by Horst, Koszewski and Reinhardt give possible insight into the tion, there was significantly less urinary Ca and P excretion with the 19-nor treatment. For bone resorption studdifference in toxicity between vitamin D 2 and vitamin D 3 [42] . Under physiological conditions they showed that ies, PTX rats treated with either analog were fed diets deficient in either Ca or P. This was done to eliminate any the predominant monohydroxylated form of vitamins D 2 and D 3 is 25-(OH)D, but that in vitamin D 2 -treated rats contribution of intestinal Ca or P absorption to serum Ca or P, allowing for an indirect measurement of bone approximately 20% is 24-(OH)D 2 . In contrast, when the
